Merus (NASDAQ:MRUS – Get Free Report) COO Peter B. Silverman sold 10,000 shares of the stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Merus Trading Down 1.7 %
Shares of Merus stock traded down $1.03 on Friday, reaching $59.17. 1,163,148 shares of the stock were exchanged, compared to its average volume of 796,041. The firm has a market capitalization of $3.47 billion, a PE ratio of -21.73 and a beta of 1.10. Merus has a 1-year low of $19.81 and a 1-year high of $61.61. The business has a fifty day moving average price of $50.10 and a two-hundred day moving average price of $42.52.
Merus (NASDAQ:MRUS – Get Free Report) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.24. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. The firm had revenue of $7.89 million for the quarter, compared to the consensus estimate of $8.94 million. Research analysts expect that Merus will post -3.1 EPS for the current year.
Analyst Upgrades and Downgrades
Institutional Investors Weigh In On Merus
Institutional investors and hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD purchased a new stake in shares of Merus in the first quarter valued at about $53,377,000. RTW Investments LP increased its position in Merus by 90.0% during the 3rd quarter. RTW Investments LP now owns 1,996,764 shares of the biotechnology company’s stock worth $47,084,000 after purchasing an additional 945,871 shares in the last quarter. Federated Hermes Inc. raised its stake in Merus by 26.0% in the 4th quarter. Federated Hermes Inc. now owns 3,637,309 shares of the biotechnology company’s stock valued at $100,026,000 after purchasing an additional 751,609 shares during the last quarter. Artal Group S.A. purchased a new position in Merus in the 1st quarter valued at about $20,492,000. Finally, Avoro Capital Advisors LLC boosted its stake in shares of Merus by 100.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 888,888 shares of the biotechnology company’s stock worth $24,444,000 after purchasing an additional 444,444 shares during the last quarter. 96.14% of the stock is currently owned by hedge funds and other institutional investors.
About Merus
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Featured Stories
- Five stocks we like better than Merus
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What is the Nikkei 225 index?
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What Is WallStreetBets and What Stocks Are They Targeting?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.